Clinically, p53-mutant diffuse large B cell lymphoma (DLBCL) demonstrates significantly worse outcomes when treated with anti-CD19 CAR-T therapy, showing a complete response (CR) rate of 34%, markedly lower than the 65% CR rate observed in p53-WT patients [71]. Here, CD19 is linked to diffuse large B-cell lymphoma.